Hull Brynley, Hendry Alexandra, Dey Aditi, Brotherton Julia, Macartney Kristine, Beard Frank
National Centre for Immunisation Research and Surveillance; The Children's Hospital at Westmead; The University of Sydney.
Commun Dis Intell (2018). 2025 Feb 6;49. doi: 10.33321/cdi.2025.49.023.
We analysed Australian Immunisation Register (AIR) data, predominantly for National Immunisation Program funded vaccines, as at 2 April 2023 for children, adolescents and adults, focusing on the calendar year 2022 and on trends from previous years. This report aims to provide comprehensive analysis and interpretation of vaccination coverage data to inform immunisation policy and programs.
Fully vaccinated coverage in Australian children in 2022 was 0.6-1.1 percentage points lower than in 2021 at the 12-month (93.3%), 24-month (91.0%) and 60-month (93.4%) age assessment milestones. This follows the 0.6-0.8 percentage point decrease at the 12- and 60-month milestones between the 2020 and 2021 reports, which came after eight years of generally increasing coverage. Due to the lag time involved in assessment, fully vaccinated coverage figures for 2021 and 2022 predominantly reflect vaccinations due in 2020 and 2021, respectively, and therefore reflect impacts of the first two years of the coronavirus disease 2019 (COVID-19) pandemic. Fully vaccinated coverage in Aboriginal and Torres Strait Islander (hereafter, respectfully, Indigenous) children was 1.2-2.2 percentage points lower in 2022 than in 2021 at the 12-month (90.0%), 24-month (87.9%) and 60-month (95.1%) milestones, indicating differential impacts of the pandemic. However, at the 60-month milestone, coverage in Indigenous children was 1.7 percentage points higher than in children overall. There were also clear pandemic impacts on on-time (within 30 days of recommended age) vaccination. On-time coverage of both the second dose of diphtheria-tetanus-pertussis and the first dose of measles-mumps-rubella-containing vaccines decreased progressively from mid-2020 onwards (6 and 12 percentage point falls, respectively) before recovering partially in the second half of 2022, with decreases 1.5-2.3 percentage points greater in Indigenous than non-Indigenous children, from an already close to 10 percentage points lower pre-pandemic baseline.
Of adolescents turning 15 years in 2022, a total of 85.3% of girls and 83.1% of boys (83.0% and 78.1% of Indigenous girls and boys) had received at least one dose of human papillomavirus (HPV) vaccine by their fifteenth birthday, 0.9-1.3 percentage points lower than in 2021 (2.5-3.1 percentage points for Indigenous adolescents), also reflecting pandemic impacts. It will be important to monitor coverage with the single-dose HPV vaccine schedule - which was implemented from February 2023 - to ensure that it is sustained (ideally, increasing) and equitable, given that coverage in 2022 was 5-6 percentage points lower in adolescents in socioeconomically disadvantaged and remote areas. By 31 December 2022, coverage for an adolescent dose of diphtheria-tetanus-acellular pertussis vaccine in adolescents turning 15 years in 2022 was 86.9% (82.6% for Indigenous adolescents) and coverage for an adolescent dose of meningococcal ACWY vaccine in those turning 17 years was 75.9% (65.6% for Indigenous adolescents). Ongoing adolescent coverage gaps warrant tailored strategies to achieve higher vaccine uptake.
Zoster vaccination coverage in 2022 was 41.3% in adults turning 71 years (37.7% in Indigenous adults), 2.6 (3.6) percentage points higher than in 2021, and was highest in adults turning 75 years (54.6% and 54.0%), reflecting a combination of vaccination at 70 years and catch-up at older ages. Coverage of 13-valent pneumococcal conjugate vaccine (13vPCV) was 33.8% in adults turning 70 years in 2022 (37.7% in Indigenous adults), 9.9 (12.6) percentage points higher than in 2021. These increases may be partly due to more complete reporting following the introduction of mandatory reporting to the AIR in mid-2021. Influenza vaccination coverage in adults in 2022 increased with increasing age, reaching 73.0% in the ≥ 75 years age group. Coverage was higher in 2022 than in 2021 across all adult age groups, with the proportionate increase since 2019 four- to five-fold higher in those aged < 65 years than in those aged ≥ 65 years. This likely reflects increased completeness due to mandatory reporting, with coverage previously substantially underestimated in younger adults.
Vaccination coverage in children and adolescents decreased modestly in 2022, reflecting impacts of the COVID-19 pandemic, but remained relatively high in global terms. The decrease in coverage was greater in Indigenous children and adolescents, with timeliness of vaccination an ongoing issue exacerbated by the pandemic. While adult coverage increased in 2022 - likely, in part, due to the introduction of mandatory reporting to AIR resulting in more accurate estimates - it remains suboptimal. Limited evidence suggests the lower coverage in children and adolescents is due to a combination of acceptance and access factors. Particularly given the evidence that these modest declines in coverage have continued into the first half of 2023, further exploration is needed to better understand these factors and to inform approaches to effectively address barriers and increase vaccine uptake.
我们分析了截至2023年4月2日澳大利亚免疫登记册(AIR)的数据,主要涉及国家免疫规划资助的疫苗,涵盖儿童、青少年和成年人,重点关注2022年日历年以及前几年的趋势。本报告旨在对疫苗接种覆盖率数据进行全面分析和解读,为免疫政策和项目提供参考。
2022年澳大利亚儿童在12个月(93.3%)、24个月(91.0%)和60个月(93.4%)年龄评估里程碑时的全程接种覆盖率比2021年低0.6 - 1.1个百分点。在2020年和2021年报告中,12个月和60个月里程碑时的覆盖率下降了0.6 - 0.8个百分点,此前八年覆盖率总体呈上升趋势。由于评估存在滞后性,2021年和2022年的全程接种覆盖率数据主要分别反映2020年和2021年应接种的疫苗,因此反映了2019冠状病毒病(COVID - 19)大流行头两年的影响。2022年,原住民和托雷斯海峡岛民(以下简称原住民)儿童在12个月(90.0%)、24个月(87.9%)和60个月(95.1%)里程碑时的全程接种覆盖率比2021年低1.2 - 2.2个百分点,表明大流行产生了不同影响。然而,在60个月里程碑时,原住民儿童的覆盖率比所有儿童的总体覆盖率高1.7个百分点。大流行对按时(在建议年龄的30天内)接种疫苗也有明显影响。白喉 - 破伤风 - 百日咳联合疫苗第二剂和含麻疹 - 腮腺炎 - 风疹疫苗第一剂的按时接种覆盖率从2020年年中开始逐渐下降(分别下降6和12个百分点),在2022年下半年部分恢复,原住民儿童的下降幅度比非原住民儿童大1.5 - 2.3个百分点,且下降幅度比大流行前已经接近低10个百分点的基线还要大。
在2022年满15岁的青少年中,共有85.3%的女孩和83.1%的男孩(原住民女孩和男孩分别为83.0%和78.1%)在15岁生日前至少接种了一剂人乳头瘤病毒(HPV)疫苗,比2021年低0.9 - 1.3个百分点(原住民青少年低2.5 - 3.1个百分点),这也反映了大流行的影响。鉴于2022年社会经济弱势和偏远地区青少年的覆盖率比其他地区低5 - 6个百分点,监测自2023年2月开始实施的单剂HPV疫苗接种计划的覆盖率,以确保其持续(理想情况下是上升)且公平,将非常重要。到2022年12月31日,2022年满15岁青少年的白喉 - 破伤风 - 无细胞百日咳疫苗青少年剂量接种覆盖率为86.9%(原住民青少年为82.6%),2022年满17岁青少年的A、C、W、Y群脑膜炎球菌结合疫苗青少年剂量接种覆盖率为75.9%(原住民青少年为65.6%)。持续存在的青少年接种覆盖率差距需要制定针对性策略以提高疫苗接种率。
2022年,71岁成年人的带状疱疹疫苗接种覆盖率为41.3%(原住民成年人为37.7%),比2021年高2.6(3.6)个百分点,在75岁成年人中最高(分别为54.6%和54.0%),这反映了70岁时的接种情况以及老年时的补种情况。2022年,70岁成年人的13价肺炎球菌结合疫苗(13vPCV)接种覆盖率为33.8%(原住民成年人为37.7%),比2021年高9.9(12.6)个百分点。这些增长可能部分归因于2021年年中对AIR实施强制报告后报告更加完整。2022年成年人的流感疫苗接种覆盖率随年龄增长而增加,在≥75岁年龄组达到73.0%。2022年所有成年年龄组的覆盖率均高于2021年,自2019年以来,<65岁人群的覆盖率增长比例比≥65岁人群高四至五倍。这可能反映了强制报告导致的完整性增加,此前年轻成年人的覆盖率被大幅低估。
2022年儿童和青少年的疫苗接种覆盖率略有下降,反映了COVID - 19大流行的影响,但从全球来看仍相对较高。原住民儿童和青少年的覆盖率下降幅度更大,疫苗接种的及时性仍是一个因大流行而加剧的持续问题。虽然2022年成年人的接种覆盖率有所上升——部分可能是由于对AIR实施强制报告导致估计更准确——但仍未达到最佳水平。有限的证据表明,儿童和青少年覆盖率较低是接受度和可及性因素共同作用的结果。特别是鉴于有证据表明这些覆盖率的适度下降持续到了2023年上半年,需要进一步探索以更好地理解这些因素,并为有效解决障碍和提高疫苗接种率提供方法依据。